柔红霉素聚氰基丙烯酸正丁酯毫微粒体外逆转白血病细胞多药耐药性  

Reversion of multidrug resistance of leukemic cells using daunorubicin polybutylcyanoacrylate nanoparticles in vitro

作　　者：彭应旭[1,2,3] 庄燕黎[1,2,3] 彭文珍 廖工铁[1,2,3] 

机构地区：[1]上海医药工业研究院 [2]华西医科大学分子生物学研究室 [3]华西医科大学药学院

出　　处：《中国药学杂志》1999年第7期461-463,共3页Chinese Pharmaceutical Journal

摘　　要：目的：研究柔红霉素聚氰基丙烯酸正丁酯毫微粒（ＤＮＲＰＢＣＡＮＰ）能否逆转白血病细胞的多药耐药性。方法：以噻唑蓝（ＭＴＴ）比色法评价ＤＮＲ，ＤＮＲＰＢＣＡＮＰ，ＰＢＣＡＮＰ对白血病细胞敏感株、耐药株的细胞毒性。结果：ＤＮＲ对耐药株的细胞毒作用降低８倍，而ＤＮＲＰＢＣＡＮＰ对敏感株、耐药株的细胞毒作用保持不变。结论：ＤＮＲＰＢＣＡＮＰ可逆转白血病细胞的多药耐药性。BJECTIVE: To study the reversion of multidrug resistance of leukemic murine cells using daunorubicin polybutylcyanoacrylate nanoparticles (DNRPBCANP)in vitro. METHODS: The cytotoxicity of DNR, DNRPBCANP and PBCANP were determined by measuring the inhibition of cell growth using the tetrazolium dye (MTT) assay. RESULT: DNRPBCANP showed the same cytotoxic effect for sensitive and resistant cells, but free DNR decreased the cytotoxic effect in the case of resistant cells by 8 fold. CONCLUSION: DNRPBCANP was effective to overcome the multidrug resistance.

关 键 词：柔红霉素 多药耐药性 逆转 DNR-PBCA-NP 白血病 

分 类 号：R733.705[医药卫生—肿瘤] R730.5[医药卫生—临床医学]